Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect of HSG4112 in Healthy Male Volunteers
NCT04733001Phase 1Completed
- Sponsor
- Glaceum
- Start
- Jul 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vutiglabridin in obesity (3 arms), sponsored by Glaceum. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Hour 0 to 24, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Point and 1 more. Started Jul 2020; status: completed.
02
Drugs
vutiglabridin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04733001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04733001.